Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, One-Sequence Study to Evaluate the Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone

Next Previous
Trial Profile

An Open-Label, One-Sequence Study to Evaluate the Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risperidone (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Pharmacokinetics; Registrational
  • Acronyms BORIS
  • Sponsors Rovi

    • Most Recent Events

    • 31 Jan 2020 According to an Rovi Media release, after the conclusion of the validation phase, the European health authorities have commenced the assessment process to grant marketing authorisation for Doria in the European Union (EU).
    • 31 Jan 2020 According to an Rovi Media release, the company has filed its application for marketing authorisation for Doria with the European health authorities, the European Medicines Agency (EMA), through the Centralised Procedure on 27 December, 2019. After passing the validation phase satisfactorily, the dossier was admitted for evaluation on 30 January, 2020.
    • 30 Jul 2019 According to an Rovi Media release, the company will include long-term safety data on more than 100 patients exposed to at least one year of treatment with Doria in the registration dossier, as recommended in the International Conference on Harmonization (ICH) Guideline E1.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top